Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Terumo Interventional Systems Statement Regarding Production (COVID-19)

17/03/2020 - Tokyo, Japan

Dear Valued Customer,

With respect to your inquiries about business continuity related to the novel coronavirus (COVID-19) pandemic, Terumo Interventional Systems abides by the following three key policies which are in line with Terumo’s Group Mission, our Core Values and our robust Business Continuity Plan.
  1. Our top priority is to protect the health and safety of all Terumo Associates.
  2. Maintain a stable supply of product so we can continue to meet global healthcare needs
  3. Actively engage so we can contribute to the prevention and treatment of disease by maximizing Terumo Group expertise and technologies

To date, we can confirm there is no serious disruption to our supply chain for Terumo Interventional Systems products. Our manufacturing sites across the world are fully operational and our product supply levels are stable.

Furthermore, we can confirm there is no serious downstream impact to our supply chain. We have proactively reached out to our Terumo Interventional Systems suppliers and logistics partners and are remaining in close contact with them to monitor and help ensure we continue to maintain a stable supply of raw materials and components – and our operations continue to run smoothly.

In response to the growing global risk, each of our manufacturing sites has implemented strict countermeasures to prevent the spread of COVID-19, taking necessary precautions to safeguard the health of our associates and protect our production processes. Some examples of these countermeasures include: restriction of movement between business locations, requesting non-production associates to work from home, and staggering work shifts and cafeteria usage times. Terumo will continue to carry out these countermeasures to minimize the risk of our associates contracting COVID-19 and to maintain productivity.

In line with our Group Mission of "Contributing to Society through Healthcare," Terumo Interventional Systems is committed to providing our customers with uninterrupted, reliable product supply and to minimizing the impact on the healthcare systems that serve us all.

Finally, for those customers proactively limiting access and interaction for the greater good and protection of their healthcare professionals and patients, we remain in constant contact and, as always, available to provide vital support and service as needed throughout this crisis.

We understand this is a dynamic situation and are fully committed to keeping you informed. Please contact us through your normal channels if you have further questions.

Sincerely,

Hikaru Samejima
Managing Executive Officer
President, Cardiac and Vascular Company
Terumo Corporation